High circulating levels of Periostin are associated with a poor survival in primary, non-metastatic breast cancer patients
Periostin functions as a ligand for integrins to support adhesion and migration of tumor cells which leads to increased cell survival, invasion, angiogenesis and metastasis in different cancer types including breast cancer (BC).
In a recent study using the Biomedica Human Periostin ELISA, Periostin levels were significantly increased in women with primary, non-metastatic breast cancer over 60 as well as in postmenopausal women. No difference was observed in patients with and without the presence of disseminated tumor cells. However, high levels of circulating Periostin were associated with a poorer BC specific survival. These results warrant further studies on the role of Periostin in cancer patients.
More information on the Biomedica Periostin assays can be found here.
Hoffman et al. High circulating levels of Periostin are associated with a poor survival in primary, non-metastatic breast cancer patients. Am Ass Cancer Res 2019; 79(4 Suppl):Abstract nr P6-09-08